Inovio Pharmaceuticals, Inc. has entered into a partnership with the AIDS Malignancy Consortium to evaluate VGX-3100 as a potential therapy for HIV-positive adult men and women.
The Plymouth Meeting-biopharmaceutical company is developing VGX-3100, an immunotherapy designed to boost the ability of person’s immune system to fight diseases, as a treatment for human papillomavirus (HPV)-associated precancerous conditions, writes John George at bizjournals.com.
[uam_ad id=”54865″]
The AIDS Malignancy Consortium is a National Cancer Institute-supported clinical trials group founded in 1995 to support innovative trials for AIDS-related cancers. The consortium is composed of 36 clinical trials sites worldwide, five working groups, an administrative office, a statistical office, and an operations and data management office.
Dr. J. Joseph Kim, president and CEO of Inovio Pharmaceuticals, said the potential expansion of VGX-3100 to treat anal dysplasia “represents a significant increase in commercial potential” for what is his company’s lead product candidate.
[uam_ad id=”54875″]
